Phase 3 N=103 Study of Ruxolitinib Cream in Adolescents With Atopic Dermatitis
Atopic Dermatitis (AD)
Primary: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 42 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=11 Subcutaneous Hydrocortisone Children With Congenital Adrenal Hyperplasia
Congenital Adrenal Hyperplasia · Hyperplasia · Adrenal Hyperplasia
Primary: Cortisol Exposure — 110 hr*mcg/dL
N/A N=192 Trial of Integrated Smoking Cessation, Exercise and Weight Management in Serious Mental Illness: TRIUMPH
Mental Illness
Primary: Number of Participants With Smoking Abstinence — 27; 6 Participants
Phase 2 N=15 COVID Protection After Transplant - Sanofi GSK (CPAT-SG) Study
COVID-19 · Kidney Transplant
Primary: The Proportion of Participants Who Reach a SARS-CoV-2 S Antibody Level >5000 U/mL — 0 Participants
N/A N=22 Mindful After Cancer: A Mindfulness-based Therapy Intervention for Sexual Health After Cancer
Breast Cancer · Gynecologic Cancer
Primary: Feasibility/ Enrollment in the Study — 78.6 Percentage enrolled of eligible
Phase 4 N=103 Bacteriostatic Saline as a Local Anesthetic in Minor Eyelid Procedures
Eyelid Tumor · Eyelid Bump · Eyelid Deformity
Primary: Pain on Injection — 2.8; 3.6 score on a scale
N/A N=26 PS128 May Improve Off Duration on Parkinson's Disease
Parkinson Disease
Primary: Change in Unified Parkinson's Disease Rating Scale (UPDRS) — 33.00; 29.24 score on a scale — p=0.003
N/A N=217 An Evaluation of MBSR and CBT for Veterans With Chronic Pain
Chronic Pain · Pain
Primary: Pain Interference Subscale of Brief Pain Inventory (BPI) — 4.7; 4.8; 4.9; 4.4 score on a scale
Phase 4 N=72 Clinical Trial of Niagen to Examine Recovery in People With Persistent Cognitive and Physical Symptoms After COVID-19
Covid19 · Sequelae of; Infection · Cognitive Symptom
Primary: Effect of Niagen on NAD+ and Cognitive Functioning — -0.104; -0.214; -0.014; -0.147 units on a scale
Phase 2 N=6 Pozelimab and Cemdisiran Combination Therapy in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria Who Switch From Eculizumab Therapy
Paroxysmal Nocturnal Hemoglobinuria
Primary: OLTP: Number of Participants With Treatment-emergent Adverse Events (TEAEs) — 6 Participants
Early Phase 1 N=21 New Tool to Enhance Post-stroke Upper Extremity Disability
Stroke
Primary: Change in Action Research Arm Test (ARAT) Total Score From Baseline to Post-Intervention — 0.72; 0 Units on a scale
N/A N=42 Ambispective Study Evaluating the Clinical Results of SAGITTA EVL R Revision Stems
Hip Arthropathy
Primary: Survival Rate at Mid Term Follow-up — 90.1 percentage of implant survival
N/A N=113 A Clinical Study to Evaluate the Anti-Sensitivity Efficacy of a Stannous Fluoride Toothpaste in a Population of Dentin Hypersensitivity Sufferers
Dentin Sensitivity
Primary: Adjusted Mean Change From Baseline in Schiff Sensitivity Score at Day 56 — -1.40; -0.33 score on a scale — p=<0.0001
Phase 1 N=32 Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)
Carcinoma, Non-Small-Cell Lung
Primary: Number of Patients With Dose Limiting Toxicities (DLT) - Part A — 0; 0 Participants
N/A N=118 Next Generation Cataract and Vitreoretinal Surgery Study
Vitreoretinal Disease With or Without Cataracts
Primary: Percent of 'Yes' Responses to the Binary Question: "Did UNITY VCS Using Vitreoretinal or Combined Surgical Functionality Perform Per the Intended Use as Defined in…